Investigating the role of specific proteins in mantle cell lymphoma
Official title: Role of ubiquitin ligases in mantle cell lymphoma
Funded at University of Utah · NIH-11063058 · Data updated 2026-11-12
This study is looking into how a specific protein called UBR5 affects the growth of mantle cell lymphoma, a rare type of blood cancer, to find new ways to help patients with this condition.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project start | August 1, 2021 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $40,645 |
| NIH project number | 3R37CA262635-04S1 |
| Project ID | NIH-11063058 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with mantle cell lymphoma, particularly those with specific genetic mutations.
✕Less likely to help
Patients with other types of lymphoma or those without the relevant genetic mutations may not benefit from this research.
What this research studies
This research focuses on understanding the molecular mechanisms behind mantle cell lymphoma (MCL), a rare and aggressive form of non-Hodgkin's lymphoma. The study specifically examines the role of ubiquitin E3 ligases, particularly UBR5, in the development and progression of MCL. Using advanced techniques like CRISPR/Cas9, researchers are creating mouse models to explore how mutations in UBR5 affect B-lymphocyte development and the overall disease process. By analyzing these mechanisms, the research aims to identify potential new therapeutic targets for MCL patients.
Why it matters
Potential benefit: If successful, this research could lead to the development of novel treatments for mantle cell lymphoma, improving outcomes for patients.
How similar studies have gone: Previous research has shown promising results in targeting similar molecular pathways in other types of cancers, suggesting potential for success in this area as well.
Where this research is happening
-
University of Utah
Salt Lake City, United States Active
Researchers
- Principal investigator: Buckley, Shannon — University of Utah
- Study coordinator: Buckley, Shannon
Related research
Other NIH-funded projects on the same topics.
-
Cyclin D1 and DNA Repair in Mantle Cell Lymphoma: A Path to New Therapies
A clinician-researcher at Mayo Clinic is pursuing advanced training and research to understand how Cyclin D1 drives replication stress and to explore new targeted treatments for high-risk mantle cell lymphoma.
-
Duvelisib for preventing cytokine release syndrome in CAR T-cell therapy patients
A study tests whether taking duvelisib before CAR T-cell therapy can prevent dangerous inflammatory reactions in patients with large B-cell or mantle cell lymphoma.
-
ERBB signaling and ibrutinib resistance in mantle cell lymphoma
A short, patient-friendly look at how scientists study why some mantle cell lymphoma patients stop responding to ibrutinib and how ERBB signaling might be involved.
-
Why some mantle cell lymphomas respond to Notch-blocking drugs
Researchers are looking at DNA regulatory changes to understand why some mantle cell lymphomas respond to drugs that block Notch while others resist them.
-
Preventing a serious side effect of CAR T-cell therapy for lymphoma
This project is testing a new medication called Duvelisib to help prevent a serious immune reaction called cytokine release syndrome in people with large cell or mantle cell lymphoma who are receiving CAR T-cell therapy.
-
Understanding CEACAM1 in Mantle Cell Lymphoma and New Treatments
This research looks for new ways to treat mantle cell lymphoma, especially for patients whose current medications are not working well.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.